NLRP3 and stroke disorder: CY-09 inhibits NLRP3 activation by binding to the Walker A motif of NLRP3 and reducing NLRP3 binding to ATP; similar to MCC950, it inhibits NLRP3-dependent inflammatory diseases and could be a potential drug for the treatment of stroke [83].